Prevalence and related factors of healthy aging: A systematic review and meta-analysis
Abstract
Background Healthy aging is a key goal of global public health and aging policy initiatives. Understanding its prevalence and associated determinants is essential for designing targeted interventions and promoting well-being among older adults. Objective This study aimed to estimate the global prevalence of healthy aging and to identify its associated factors across different countries. Methods A systematic review and meta-analysis were conducted. A comprehensive literature search was conducted in Web of Science, PubMed, EBSCO Discovery Service (EDS), Scopus, and ProQuest from database inception to February 2025. Two independent reviewers screened articles, extracted data, and assessed study quality using the Newcastle-Ottawa Quality Assessment Scale (NOS) and the Agency for Healthcare Research and Quality (AHRQ) Methodology Checklist. Eligible studies were included in a meta-analysis using Stata 18.0 and R version 4.5.0. Results A total of 39 studies involving 300,624 participants were included. The pooled prevalence of healthy aging was 23.0% (95% CI: 18%–27%). After adjusting for publication bias using the trim-and-fill method, the estimate decreased to 15.6% (95% CI: 11.0%–20.1%), suggesting possible overestimation in the original estimate. Significant associations with healthy aging were found for age (≥75 years), gender, marital status, educational level, economic level, social participation, employment status, economy, smoking status, alcohol consumption, physical…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 300,624 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.